A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

Sponsor:

Dualitybio, Inc.

Sponsor Study ID:

DB-1311-201

CTO #:

104200

NCT Number:

NCT06953089

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Cervix Uteri; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin

Study Objectives:

To determine the RP2D of DB-1311 in combination with BNT327 by assessing the safety and tolerability in targeted participant populations. To determine the RP2D of DB-1311 in combination with DB-1305 by assessing the safety and tolerability in targeted participant populations.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)